C
15.04
-0.05 (-0.33%)
| Previous Close | 15.09 |
| Open | 15.05 |
| Volume | 226,881 |
| Avg. Volume (3M) | 594,059 |
| Market Cap | 1,941,393,280 |
| Price / Sales | 271.24 |
| Price / Book | 4.64 |
| 52 Weeks Range |
| Operating Margin (TTM) | -2,358.86% |
| Diluted EPS (TTM) | -1.52 |
| Total Debt/Equity (MRQ) | 15.17% |
| Current Ratio (MRQ) | 13.29 |
| Operating Cash Flow (TTM) | -146.31 M |
| Levered Free Cash Flow (TTM) | -91.92 M |
| Return on Assets (TTM) | -20.47% |
| Return on Equity (TTM) | -42.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Centessa Pharmaceuticals plc | Bullish | Bullish |
AIStockmoo Score
0.2
| Analyst Consensus | 1.5 |
| Insider Activity | -1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 0.5 |
| Average | 0.20 |
|
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.32% |
| % Held by Institutions | 92.52% |
| 52 Weeks Range | ||
| Median | 28.00 (86.17%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 15 Nov 2024 | 28.00 (86.17%) | Buy | 16.00 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2024 | Announcement | Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update |
| 12 Nov 2024 | Announcement | Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update |
| 04 Nov 2024 | Announcement | Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 26 Sep 2024 | Announcement | Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |